Core Insights - POET Technologies Inc. has received a production order exceeding US$5 million for its POET Infinity™ optical engines, intended for AI data servers [1][2][3] - The order signifies the commercial viability and scalability of POET's technology, which is designed to support AI connectivity and meet the demands of hyperscale data centers [2][5] - The optical engines are scheduled for delivery in the second half of 2026, with specific configurations including 400G transmit and 800G receive engines [3][4] Company Overview - POET Technologies specializes in high-speed optical modules, optical engines, and light source products for the AI systems market and hyperscale data centers [6] - The company's technology is based on the POET Optical Interposer™, which integrates electronic and photonic devices into a single chip, offering lower costs, reduced power consumption, and smaller sizes compared to traditional products [6] - POET's products are scalable for high production volumes and address challenges in various applications, including AI clusters, 5G networks, and autonomous vehicle systems [6] Market Outlook - The market for optical transceivers and related products is projected to double from US$5 billion in 2024 to US$10 billion by 2026, driven by the growth of AI clusters [5]

Core Viewpoint - Nurix Therapeutics, Inc. has announced the pricing of its underwritten registered offering of 24,485,799 shares at $10.21 per share, aiming to raise approximately $250 million for clinical development and research activities [1][4]. Group 1: Offering Details - The offering consists of 24,485,799 shares priced at $10.21 each, with expected gross proceeds of $250 million before expenses [1]. - The offering is set to close on or about October 23, 2025, pending customary closing conditions [1]. - Participation in the offering includes both new and existing investors such as General Atlantic and Redmile Group [2]. Group 2: Use of Proceeds - Nurix intends to use the net proceeds primarily for clinical development of drug candidates, including bexobrutideg (NX-5948) for chronic lymphocytic leukemia (CLL) and potential autoimmune indications [4]. - Additional uses include funding research and development to expand the pipeline, as well as for working capital and general corporate purposes [4]. Group 3: Management and Registration - J.P. Morgan Securities LLC, Jefferies LLC, and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering [3]. - The offering is made under a shelf registration statement previously filed with the SEC, which was declared effective on June 11, 2024 [5].

Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships in Biodefense InnovationHALIFAX, Nova Scotia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTC Pink: APLIF) (“Appili” or the “Company”) today announced that it will attend the Biomedical Advanced Research and Development Authority (BARDA) Innovation Symposium on November 20, 2025, in Washington, D.C. The event brings together leaders from government, industry, and academia to advance the develop ...

Core Insights - Gilat Satellite Networks Ltd. will release its third quarter 2025 financial results on November 12, 2025 [1] - The conference call will feature CEO Adi Sfadia and CFO Gil Benyamini discussing the results and business achievements [2] Company Overview - Gilat Satellite Networks is a leading global provider of satellite-based broadband communications with over 35 years of experience [3] - The company develops deep technology solutions for satellite, ground, and new space connectivity, focusing on critical connectivity for commercial and defense applications [3] Product and Service Offerings - Gilat offers integrated solutions supporting multi-orbit constellations, Very High Throughput Satellites (VHTS), and Software-Defined Satellites (SDS) [4] - The product portfolio includes cloud-based platforms, high-performance satellite terminals, advanced antennas, Solid State Power Amplifiers (SSPA), and Block Upconverters (BUC) [4] Market Applications - Gilat's products support various applications including government and defense, in-flight connectivity, broadband access, cellular backhaul, enterprise, aerospace, broadcast, and critical infrastructure [5]

Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera’s dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The agreement includes 1) an upfront payment of $3.5 million, 2) potential future regulatory milestones, commercial milestones, and contingent value rights of up to $105 million. Biossil assumes all further obligations to Blackstone Life Sciences under the 2018 Amended and Restated Purchase and Sale Agreement (the Ro ...

Core Insights - Village Farms International, Inc. has launched an innovative one-way aroma valve in its Pure Sunfarms brand packaging, allowing consumers to smell the cannabis flower before purchase, marking a first in Canada [1][2][3] Company Overview - Village Farms is a large-scale, vertically-integrated supplier of plant-based Consumer Packaged Goods, leveraging decades of experience in Controlled Environment Agriculture [5] - The company operates one of the largest cannabis operations globally, with 2.2 million square feet of greenhouse production in Canada, and is recognized as a low-cost producer with high-quality products [6] Product Innovation - The one-way aroma valve is pressure-activated, enabling the release of the flower's scent when squeezed, while preventing air and contaminants from entering the package, enhancing the consumer experience [2][3] - This innovation follows the introduction of window packaging, furthering the mission to make cannabis shopping more accessible and informative [3][4] Market Expansion - Village Farms is targeting international cannabis opportunities, exporting medical cannabis to markets such as Germany, the UK, Israel, Australia, and New Zealand, and expanding its export business [7] - The company plans to enter the US THC market, utilizing its Texas-based greenhouse assets for future growth [8]

Core Insights - Old National Bancorp reported a net income applicable to common shares of $178.5 million for Q3 2025, with a diluted EPS of $0.46. Adjusted figures show a net income of $231.3 million and an adjusted EPS of $0.59 [1][4]. Financial Performance - Net interest income on a fully taxable equivalent basis reached $582.6 million, with a net interest margin (NIM) of 3.64%, reflecting an increase of 11 basis points [2][11]. - Pre-provision net revenue (PPNR) was reported at $267.3 million, with an adjusted PPNR of $336.6 million, marking a 16% increase [2]. - Noninterest income totaled $130.5 million, with organic growth and record capital markets revenue contributing to this figure [2][11]. Expenses and Efficiency - Noninterest expenses were $445.7 million, including $69.3 million in merger-related charges. Adjusted noninterest expenses were $376.5 million [2][11]. - The efficiency ratio stood at 58.8%, while the adjusted efficiency ratio was 48.1%, indicating improved operational efficiency [2][11]. Deposits and Loans - Total deposits at the end of the period were $55.0 billion, reflecting a 4.8% annualized growth, with core deposits increasing by 5.8% [2][11]. - Total loans amounted to $48.0 billion, with a 0.6% annualized increase. Excluding loans acquired from Bremer, total loans grew by 3.1% [2][11]. Credit Quality - The provision for credit losses was $26.7 million, with net charge-offs of $30.0 million, representing 25 basis points of average loans [2][11]. - 30+ day delinquencies were at 0.18%, and nonaccrual loans accounted for 1.23% of total loans, indicating resilient credit quality [2][11]. Capital Position - Return on average tangible common equity (ROATCE) was reported at 15.9%, with an adjusted ROATCE of 20.1% [2]. - Preliminary regulatory Tier 1 common equity to risk-weighted assets was 11.02%, up 28 basis points [2][11].

Core Insights - Atea Pharmaceuticals is hosting a virtual key opinion leader (KOL) event on November 13, 2025, to discuss hepatitis C virus (HCV) topics, including patient demographics, early diagnosis, treatment importance, public policy, and potential new therapies [1][2] Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics for serious viral diseases, particularly HCV [16] - The company is advancing a global Phase 3 clinical development program for its lead regimen, bemnifosbuvir and ruzasvir, which targets HCV [2][9] Clinical Development - The Phase 3 program includes two trials: C-BEYOND in the US and Canada, and C-FORWARD outside North America, each enrolling approximately 880 treatment-naïve patients [9] - The trials compare the fixed-dose combination of bemnifosbuvir and ruzasvir to the existing regimen of sofosbuvir and velpatasvir, with treatment durations of 8 to 12 weeks depending on cirrhosis status [9][10] Efficacy and Safety - Phase 2 study results indicated a 98% sustained virologic response (SVR12) rate for the bemnifosbuvir and ruzasvir regimen in treatment-adherent patients [12] - The combination has shown a low risk of drug-drug interactions and can be taken with or without food, making it suitable for co-infected patients [13] Market Opportunity - The KOL event will also cover the commercial market opportunity for HCV treatments and the potential impact of Atea's therapies on prescribers and patients [2] - HCV remains a significant global health issue, with an estimated 50 million people chronically infected worldwide and 240,000 deaths annually [11] Key Opinion Leaders - The event will feature prominent HCV experts, including Dr. Jordan Feld, Dr. Eric Lawitz, Dr. Anthony Martinez, and Dr. Nancy Reau, who will provide insights into HCV management and research [3][4][5][8]

LONDON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (‘Marex’ or the ‘Group’; NASDAQ: MRX), the diversified global financial services platform, today announces that it has agreed to acquire Valcourt SA (“Valcourt”). Valcourt is a fixed income market maker based in Geneva, Switzerland, specialising in fixed income instruments such as high-yield, subordinated, emerging markets, private, illiquid, and sustainable debt. The acquisition will add 700 clients ranging from banks, independent wealth managers an ...

AUSTIN, Texas and NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE: TE) (“T1,” “T1 Energy,” or the “Company”) has announced preliminary financial and operating results for the third quarter 2025. Preliminary Third Quarter 2025 Results Overview Total Net Sales/Modules Sales Volumes: T1 generated total net sales for the third quarter of $200 - $210 million on modules sales of approximately 725 MW.Maintaining 2025 EBITDA guidance range of $25 - $50 million. In Q4 2025, T1 expects a significant ...